Preview

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

Хронический миелоидный лейкоз у детей

https://doi.org/10.24287/1726-1708-2016-15-4-51-56

Полный текст:

Аннотация

Хронический миелоидный лейкоз (ХМЛ) у детей младше 18 лет встречается редко, в связи с этим нет четких критериев мониторинга и индивидуализации лечения в данной возрастной группе. В статье, представляющей собой обзор литературы, приведены некоторые особенности манифестации, течения ХМЛ, ответа на терапию ингибиторами тирозинкиназы и результаты аллогенной трансплантации гемопоэтических стволовых клеток у детей. Кроме того, приводятся публикуемые данные по частоте встречаемости некоторых побочных эффектов на фоне длительного приема иматиниба.

Об авторе

Марина Владимировна Борисевич
Республиканский научно-практический центр детской онкологии, гематологии и иммунологии
Россия


Список литературы

1. Ries LAG, Melbert D, Krapcho M. SEER Cancer Statistics review. Bethesda, MD: NCI, 2008.

2. CML: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. European Society for Medical Oncology. 2010.

3. Josu de la Fuente J, Baruchel A, Biondi A, Eveline de Bont, Dresse M, Suttorp M, et al. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol. 2014;167(1):33-47.

4. Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016 Jan 28;127(4):392-9. doi: 10.1182/blood-2015-06-648667. Epub 2015 Oct 28.

5. Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116(1):140-3.

6. Syasina TV, Bessmel'tsev SS, Kozlov AV. Laboratornye markery khronicheskogo mieloleikoza. Transfuziologiya i gematologiya. 2011;12(80):959-74. (In Russian).

7. Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. J Manag Care Pharm. 2007;13(8):8-12.

8. Hijiya N, Millot F, Suttorp M. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. Pediatric Clin North Am. 2011 ;62(1):107-19.

9. Millot F, Traore Ph, Guilhot J. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116(1):140-3.

10. Adler R, Viehmann S, Kuhlisch E, Martiniak Y, Röttgers S, Harbott J, et al. Correlation of BCR/ABL transcript variants with patients’characteristics in childhood chronic myeloid leukaemia. European J of Haematology. 2008;82(2):112-8.

11. Gurrea Salas D, Glauche I, Tauer JT, Thiede C, Suttorp M. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? Ann Hematology. 2015;94(8):1363-71.

12. Millot F, Guilhot J, Baruchel A, Petit A, Bertrand Y, Mazingue F. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood. 2014;124(15):2408-10.

13. Giona F, Putti MC, Micalizzi C, Menna G, Moleti ML, Santoro N, et al. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia-inchronic phase: the Italian experience. Br J Haematology. 2015; 170(3):398-407.

14. Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French National phase IV trial. J of Clinical Oncology. 2011;29(20):2827-32.

15. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of European Lukemia Net. Blood. 2006; 108(6):1809-20.

16. Shaffer LG, McGowan-Jordan J, Schmid M. An International System for Human Cytogenetic Nomenclature. 2013. Karger. Basel.

17. Marzocchi G, Castaquetto F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G, et al. Variant Philadelphia translocations: molecular, cytogenetic characterization and prognostic influence. Blood. 2011;117(25):6793-800.

18. Jones D, Luthra R, Cortes J, Thomas D, O'Brien S, Bueso-Ramos C, et al. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changed in determining the phenotype of Philadelphia chromosome-positive leukemia. Blood. 2008;15(112):5190-2.

19. Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, et al. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia. Arch Iran Med. 2008;11(3):247-51.

20. Todoric-Zivanovic B, Strnad M, Stamatovic D, Tukic L, Krtolica K, Tatomirovic Z, et al. Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia. J BUON. 2011;16(1):104-7.

21. Lucas CM, Harris J, Giannoudis A, Davies A, Davies A, Knight K, et al. Chronic myeloid leukemia in patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94(10):1362-7.

22. Aurer I, Butturini A, Gale RP. BCR/ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1991; 78(9):2407-10.

23. Suttorp M, Thiede C, Tauer JT, Range U, Schlegelberger B, von Neuhoff N. Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia. Haematologica. 2010;95(5):852-3.

24. Hasan SK, Sazawal S, Kumar B, Chaubey R, Mishra P, Mir R, et al. Childhood CML in India: b2a2 transcript is more common than b3a2. Cancer Genetic Cytogenetic. 2006;169(1):76-7.

25. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinibmesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children’s Oncology Group phase 1 study. Blood. 2004;104(9):2655-60.

26. Suttorp M, Thiede C, Tauer JT, Roettgers S, Sedlacek P, Harbott J. Chronic myeloid leukemia in pediatrics - first results from study CML-PAED II. Blood. 2009;114:145.

27. Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Bekassy AN, et al. Imatinibmesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase, and in relapse after stem cell transplantation. Leukemia. 2006;20(2):187-92.

28. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of conceptsand management recommendations of European Leukemia Net. J of Clinical Oncology. 2009;27(35):6041-51.

29. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05501569. Epub 2013 Jun 26.

30. Linga VG, Ganta RR, Kalpathi KI, Gundeti S, Rajappa SJ, Digumarti R, et al. Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase. South Asian J Cancer. 2014 0ct;3(4):203-5. doi: 10.4103/2278-330X. 142961.

31. Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem cell transplantation. Hematology -American Society of Hematology Educational Program. 2010;368-76.

32. Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014;20(2):310-22.

33. Reaman GH, Bonfiglio J, Krailo M, Tebbi CK, Leikin S, Ettinger R, et al. Cancer in adolescents and young adults. Cancer. 1993;71(10):3206-9.

34. Millot F, Claviez A, Leverger G, Corbaciglu S, Groll AH, Suttorp M. Imatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase. Pediatric Blood Cancer. 2014;61(2):355-7.

35. Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, et al. Population pharmacokinetics of imatinibmesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. 2009;63(2):229-38.

36. Druker BJ, Tamura S, Buchdunger E, Segal GM, Fanning S, Zimmermann J, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR/ABL positive cells. Nat Med. 1996;2(5):561-6.

37. Kolb EA, Pan Q, Ladanyi M, Steinherz PG. Imatinibmesylate in Philadelphia chromosome-positive leukemia in childhood. Cancer. 2003;98(12):2643-50.

38. Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011;118(26):6760-8.

39. Ghadyalpatil N, Banawali S, Kurkure P. Efficacy and tolerability of imatinibmesylate in pediatric chronic myeloid leukemia in a large cohort: Results from a tertiary care referral center in India. J Clin Oncol. 2009;27(2):15.

40. Lakshmaiah KC, Bhise R, Purohit S, Abraham LJ, Lokanatha D, Suresh TM, et al. Chronic myeloid leukemia in children and adolescents: Results of treatment with imatinibmesylate. Leuk Lymphoma. 2012;53(12):2430-3.

41. Champagne M, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children’s Oncology Group. Pediatric Blood Cancer. 2011;57(1):56-62.

42. Shenoy S, Smith FO. Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin. Bone Marrow Transplantation. 2008;41(2):141-8.

43. Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, et al. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biology Blood Marrow Transplantation. 2016;22(6):1056-63.

44. Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011 Jan 20;117(3): 755-63. doi: 10.1182/blood-2010-08-301341. Epub 2010 Oct 21.

45. Giona F, Moleti ML, De Benedittis D, Santopietro M, Nanni M, Testi AM, et al. Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplantation? A single centre experience. British J of Haematology. 2015;173(4):5-10.

46. Suttorp M, Claviez A, Bader P, Peters C, Gadner H, Ebell W, et al. Allogeneic stem cell transplantation for pediatric and adolescent patients with CML: results from the prospective trial CML-paed I. Klin Padiatr. 2009;221(6):351-7.

47. Millot F, Esperou H, Bordigoni P, Dalle JH, Michallet M, Michel G, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffede Moelle et de TherapieCellulaire (SFGM-TC). Bone Marrow Transplant. 2003;32(10):993-9.

48. Melo JV, Ross DM. Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? American society of hematology. Education program. 2011;136-42.

49. Brogile L, Hijiya N, Helenowski I, Dilley K, Schneiderman J, Tse W, et al. Long-term follow-up of children with chronic myeloid leukemia after hematopoietic stem cell transplantation and tyrosine kinase inhibitor therapy. Leukemia and lymphoma. 2016;57(4):949-52.

50. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, et al. Allogeneichematopoietic stem cell transplantation (alloSCT) for chronic myeloid leukemia in the imatinibera: evaluation of its impact within a subgroup ofthe randomized German CML Study IV. Blood. 2010;115(10):1880-5.

51. Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem celltransplantation for chronic myeloid leukemiain children. Paediatric and chronic leukaemia working parties of the European group for blood and marrow transplantation. Blood. 2003;102(4):1224-31.

52. Muramatsu H, Kojima S, Yoshimi A, Atsuta Y, Kato K, Nagatoshi Y, et al. Outcome of 125 children with chronicmyelogenous leukemia who received transplantsfrom unrelated donors: the Japan Marrow DonorProgram. Biol Blood Marrow Transplant. 2010;16(2):231-8.

53. Zwaan MC, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the innovative therapies for children with cancer consortium. J of clinical oncology. 2013; 31 (19) :2460-8.

54. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, et al. A phase II study of imatinibmesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatric blood and cancer. 2008;50(2):254-8.

55. Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Practice and Research Clinical Haematology. 2009;22(3):409-29.

56. Suttorp M, Eckardt L, Tauer JT, Millot F. Management of chronic myeloid leukemia in childhood. Curr Hematol Malig Rep. 2012;7(2):116-24.

57. Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, et al. Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. J Clin Endocrinol Metab. 2013;98(1):67-76.

58. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC. Dysregulation of boneremodeling by imatinibmesylate. Blood. 2010;115(4):766-74.

59. Bansal D, Shava U, Varma N, Trehan A, Marwaha RK. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatric Blood Cancer. 2012;59(3):481-4.


Для цитирования:


Борисевич М.В. Хронический миелоидный лейкоз у детей. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2016;15(4):51-56. https://doi.org/10.24287/1726-1708-2016-15-4-51-56

For citation:


Borisevich M.V. Chronic myeloid leukemia in children. Pediatric Hematology/Oncology and Immunopathology. 2016;15(4):51-56. (In Russ.) https://doi.org/10.24287/1726-1708-2016-15-4-51-56

Просмотров: 13


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)